DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,009,159 | -0.9% | 108,864 | -4.1% | 0.08% | +6.2% |
| Q2 2023 | $27,255,601 | +35.1% | 113,565 | +41.8% | 0.08% | +27.0% |
| Q1 2023 | $20,181,347 | -4.2% | 80,072 | +0.8% | 0.06% | -7.4% |
| Q4 2022 | $21,074,879 | +865.4% | 79,402 | +839.6% | 0.07% | +871.4% |
| Q3 2022 | $2,183,000 | +31.9% | 8,451 | +29.4% | 0.01% | +40.0% |
| Q2 2022 | $1,655,000 | +75.9% | 6,530 | +103.5% | 0.01% | +150.0% |
| Q1 2022 | $941,000 | -10.9% | 3,209 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $1,056,000 | +8.1% | 3,209 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $977,000 | +13.5% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $861,000 | +19.3% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $722,000 | +1.3% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $713,000 | +3.2% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $691,000 | +21.9% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $567,000 | +27.7% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $444,000 | -9.9% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $493,000 | +6.5% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $463,000 | +0.9% | 3,209 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $459,000 | -29.4% | 3,209 | -34.8% | 0.00% | -33.3% |
| Q1 2019 | $650,000 | +46.1% | 4,925 | +14.1% | 0.00% | +50.0% |
| Q4 2018 | $445,000 | -99.5% | 4,317 | -99.6% | 0.00% | -99.5% |
| Q3 2017 | $93,716,000 | -54.2% | 1,092,514 | -55.0% | 0.41% | -57.8% |
| Q2 2017 | $204,695,000 | -1.9% | 2,425,587 | -0.5% | 0.98% | -5.3% |
| Q1 2017 | $208,571,000 | +8.9% | 2,438,575 | -0.9% | 1.03% | +2.9% |
| Q4 2016 | $191,559,000 | +82.6% | 2,460,939 | +83.9% | 1.00% | +95.9% |
| Q3 2016 | $104,903,000 | -22.7% | 1,338,221 | -0.4% | 0.51% | -27.2% |
| Q2 2016 | $135,719,000 | +8.3% | 1,343,751 | +1.7% | 0.70% | +3.5% |
| Q1 2016 | $125,324,000 | +37.9% | 1,321,145 | +35.0% | 0.68% | +30.6% |
| Q4 2015 | $90,880,000 | +43.4% | 978,469 | +31.1% | 0.52% | +40.3% |
| Q1 2015 | $63,384,000 | -0.1% | 746,567 | +0.9% | 0.37% | -4.4% |
| Q4 2014 | $63,420,000 | +4.1% | 739,940 | -7.7% | 0.39% | +7.8% |
| Q3 2014 | $60,895,000 | -4.6% | 801,466 | -1.1% | 0.36% | -3.0% |
| Q2 2014 | $63,815,000 | +1.3% | 810,552 | -3.5% | 0.37% | -11.9% |
| Q1 2014 | $63,016,000 | -12.0% | 840,218 | -9.5% | 0.42% | -16.0% |
| Q4 2013 | $71,639,000 | +14.4% | 927,965 | +2.7% | 0.50% | +8.5% |
| Q3 2013 | $62,612,000 | +13.9% | 903,234 | +4.7% | 0.46% | +9.5% |
| Q2 2013 | $54,954,000 | – | 862,462 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |